Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Alleva, David G., Delpero, Andrea R., Scully, Melanie M., Murikipudi, Sylaja, Ragupathy, Ramya, Greaves, Emma K., Sathiyaseelan, Thillainaygam, Haworth, Jeffrey R., Shah, Nishit J., Rao, Vidhya, Nagre, Shashikant, Lancaster, Thomas M., Webb, Sarah S., Jasa, Allison I., Ronca, Shannon E., Green, Freedom M., Elyard, Hanne Andersen, Yee, JoAnn, Klein, Jeffrey, Karnes, Larry, Sollie, Frans, Zion, Todd C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491978/
https://www.ncbi.nlm.nih.gov/pubmed/34642088
http://dx.doi.org/10.1016/j.vaccine.2021.09.077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491978/
https://www.ncbi.nlm.nih.gov/pubmed/34642088
http://dx.doi.org/10.1016/j.vaccine.2021.09.077

Ejemplares similares